Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA9 | Q16790 | 12/20 | 1.00 |
| ▸ | CA1 | P00915 | 12/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667729 | 0.94 | CA2 (0.89) | CA2CA9CA1CA12CA14 | |
| SCHEMBL27565484 | 0.88 | CA2 (0.78) | CA2CA9CA1CA12CA14 | |
| SCHEMBL866410 | 0.83 | CA1 (0.71) | CA2CA9CA1CA12CA14 | |
| SCHEMBL2236145 | 0.83 | CA2 (0.69) | CA2CA9CA1CA12CA14 | |
| SCHEMBL6799583 | 0.82 | CA1 (0.68) | CA2CA9CA1CA12CA7 | |
| SCHEMBL6798465 | 0.81 | CA9 (0.78) | CA2CA9CA1CA12HTT | |
| Hydrazine SCHEMBL28200768 | 0.81 | CA1 (0.68) | CA2CA9CA1CA12CA14 | |
| SCHEMBL8690274 | 0.80 | CA1 (0.67) | CA2CA9CA1CA12CA14 | |
| Potassium Ion SCHEMBL1902294 | 0.80 | CA1 (0.67) | CA2CA9CA1CA12CA14 | |
| SCHEMBL4826239 | 0.80 | CA1 (0.67) | CA2CA9CA1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725941-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4540245-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LigaChem Biosciences Inc. (KR) | 2025-04-23 | — | — | EP | disclosed |
| CN-115151253-B | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115803024-B | Compositions comprising aryl amide derivatives | 中外制药株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-114929669-B | Aryl amide derivatives with antitumor activity | 中外制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | disclosed |
| US-20240246922-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-25 | — | — | US | disclosed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-11964950-B2 | Arylamide derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-23 | — | — | US | disclosed |
| WO-2017090743-A1 | NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2017-06-01 | — | — | WO | disclosed |
| EP-3150578-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015182723-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2015-12-03 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2219448-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | Myriad Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| US-4056544-A | Anthraquinone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021624-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | CA2 615/4885CA9 980/4885CA1 1149/4885 |
| US-20240246922-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, RAF1, NRAS | CA2 1782/4885CA9 2312/4885CA1 2850/4885 |
| US-11964950-B2 | Arylamide derivative having antitumor activity | BRAF, NRAS, KRAS | CA2 1905/4885CA9 2372/4885CA1 3224/4885 |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | BRAF, RAF1, NRAS | CA2 1342/4885CA9 2327/4885CA1 4020/4885 |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | CA2 3327/4885CA9 1710/4885CA1 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.